TOLL-FREE NUMBER ON DRUG PRODUCTS DELAYED

Published Online: Friday, February 1, 2008

Pharmacies have been given until January 1, 2009, to comply with an FDA ruling that requires a toll-free number for reporting drug side effects on the labeling of new and refill prescriptions and OTC products dispensed in an outpatient setting.

The FDA's interim rule is designed to codify the proposed rule entitled "Toll-Free Number for Reporting Adverse Events on Labeling for Human Drug Products" that, under the Food and Drug Administration Amendments Act of 2007 (FDAAA), became effective on January 1. The rule requires that drug products for which applications have been approved include a toll-free number on the label only for reporting adverse events; it is not intended for seeking medical advice. As mandated by the FDAAA, the interim final rule does not apply to OTC products approved as new drugs if their product packaging already includes a toll-free number for reporting complaints to the manufacturer or drug distributor.

The National Association of Chain Drug Stores (NACDS) has been working closely with the FDA on the impact of the new side-effect requirements. NACDS President and Chief Executive Officer Steven C. Anderson, IOM, CAE, noted that "ensuring the health and well-being of our pharmacy patients is the highest priority," and "we look forward to continuing to work with the FDA over the next year to help chain pharmacies meet the requirements by next January."



Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$
VSEO N/A